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1. Introduction 
China is becoming a strategic player in the pharmaceutical market, both as a consumer country and as a 
growing and upgrading industrial platform. 
The Government has been embracing a large reform in the healthcare system to upgrade the quality and 
coverage of healthcare assistance of Chinese people.  Multiple strategies are promoted, both on the demand 
and on the offer side. A key issue in this process is related to the transformation of the Chinese 
pharmaceutical industry: the Government is planning to build an innovative system, led by research-based 
companies. Integration of local firms with international companies has been encouraged; new specific 
measures were issued to stimulate foreign investments, improving the market access.  
To grasp knowledge, know how and best practices, the Government is willing to attract not only the 
manufacturing and marketing division of foreign firms, but it is also promoting the transfer of some of their 
critical business operations, core technologies and research development to China. 
The growth of the size of the “industry” is also due to an increased order in the market, to the exit of small 
and irregular competitors, to more stability in drug regulation and to an improved intellectual property (IP) 
protection. IP issues, in particular, play a fundamental role for the development of the market. In recent 
years, pharmaceutical is the industrial sector which has applied the highest number of patents in China: 
domestic firms are actually the main force, but patent applications and granted patents of foreign enterprises 
are increasing.  
The aim of the chapter is to give a general overview of the current characteristics of the Chinese 
pharmaceutical market, of its main trends, as well as of main changes and expected evolution of the demand 
and of the supply in the industry. We also look at the balance between foreign and national firms’ position in 
the market, in term of Western interests for Chinese traditional knowledge and culture as well. We try to 
build a general picture of the industry and of main competitors to evaluate and grasp future research 
opportunities in this area in an International Business perspective. 
The chapter is structured as follows. Paragraph 2 is focused on main trends in the Chinese pharmaceutical 
market: consumptions, production, import and export flows. Features of the industry and main competitors 
are described in Paragraph 3, while Paragraph 4 analyses the motivation of the increasing presence of global 
pharmaceutical players in China. Paragraph 5 is focused on IP trends and on the role of national firms vs 
foreign competitors.  
Before starting the analysis, a clarification is fundamental. The Chinese pharmaceutical market is a 
comprehensive industry, for manufacturing and sale of: synthetic chemicals and drugs, the so-called Western 
drugs, including OTC –over the counter medicine and prescription medicine; traditional Chinese medicines 
(TCM); medical devices, apparatus and instruments; hygiene materials; and pharmaceutical machinery. In 
this chapter we chose to focus only on Western and TCM drugs, for which the patenting issues are more 
relevant and seem to fit best our research goals. 
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2. The evolution of the market: a demand side perspective 
China is the world’s third-largest pharmaceutical market in term of sale (IMS, 2010), but it should become 
the second by 2020, behind only the United States (Yan, 2009). Several data and trends can help understand 
the speed and scope of changes undergoing in China. The market grew by 17% in 2010, reaching a value of 
$25.7 billions and accounting for 18.6% of the Asia-Pacific pharmaceutical market.  
Expenditure on health care is expected to increase from 4.7% of GDP to 6%-7% in the next few years. China 
should reach a total amount of healthcare expenditure of $705.74 by 2015 (Frost, Sullivan, 2011, p. 4), while 
per capita expenditure should be set at a level of $437 in 2016, compared to $109.5 in 2007 (Deloitte, 2011, 
p. 10). Pharmaceutical sales are spreading out as well: from 2007 to 2010 the compound annual growth rate 
was 25.9%, while through 2015 it should be 15.5% (Deloitte, 2011, p. 6). 
As a result of such facts and figures, the Chinese pharmaceutical market is becoming increasingly attractive 
to Western firms. It is considered one of the World’s most important emerging pharmaceutical areas 
(Business Monitor International Ltd, 2011). 
At the moment, sales from generics dominate the market (61.4% of the market share in 2009), but newly 
patented products are expected “to gain shares from a huge and rapidly growing absolute value market” (Jan-
Willem, 2011, p. 2).  
Data on imports of pharmaceutical products show a strong expansion (+195% of the value of flows from 
2006 to 2010), and in parallel, exports are accelerating (+135% over the same period). See Exhibit 1.	
 
Exhibit 1. Import and Export trade in Medical & Pharmaceutical Product sector (data in million US dollars) 
Source: own calculation on data provided by CeSif, Fondazione Italia Cina - Ceic 
 
From a demand-side perspective, demographic factors can be considered as one of the most relevant drivers 
of the growth of China’s pharmaceutical market.  
China is the most populous country in the World, thus resulting in a large size potential market. At the same 
time, the population is ageing, also as a consequence of the one-child policy. Many observers consider this 
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issue the country’s Achille heel: the total fertility rate is well below the replacement rate1, and the share of 
young population is decreasing rapidly2. Elderly people require appropriate, specific and long-term health 
care assistance, whose costs are much higher compared to those absorbed by young country population. 
Estimated increase of drug prescription market is between 23% and 40%, while the increase for the OTC 
market should be between 40% and 50% (Deloitte, 2010, p. 2).  
The higher sensitivity of Chinese on healthcare services and products can also be related to higher living 
standards (Yuanijia, 2007, p. 296). As the income per capita heightens, people can put more money in taking 
care of their health needs, upgrading the typical expenditure structure of consumption from basic good to 
more sophisticated goods. More and more high quality healthcare services are going to be requested by 
healthier Chinese people. 
Urbanization is another important aspect to take into account: mass migration to the cities, from the 
agricultural areas, is resulting in a growing demand for pharmaceuticals (Yuanijia, 2007, p. 296). People is 
becoming more used to new lifestyles and has an easy access to retail pharmacies. The strong commitment 
made by the Government towards the upgrading of rural infrastructure should supports this trend (Deloitte, 
2011, p. 4). 
Beside from the demographic perspective, the rising consumption of pharmaceuticals is also related to the 
evolution of the typical needs/requests of the Chinese healthcare consumer.  High longevity, combined with 
environmental and pollution problems are increasing chronic diseases like respiratory illnesses, cancer, 
diabetes, as well as obesity (Jan-Willem, 2011). New lifestyles are considered the cause of those diseases, 
sometimes called “lifestyle disease” – for which the use of lifestyle drugs are booming. Consumption of 
OTC is increasing as well, as a result of a new attitude towards self-medication. As reported by several 
surveys (Yuanjia, 2007, pp. 297-298), self medication is becoming more and more popular among Chinese 
people (Deloitte, 2011, p. 15). Since without a medical prescription, patients can only have access to OTC 
drugs, a relevant increase in this market is expected in the future. 
Last sign of the evolving Chinese consumer habits is the booming sales of drugs on line, because of the 
increasing attitude towards online shopping and the diffusion of internet3.  
The cultural and social revolution that is taking place in the healthcare habits of Chinese people has a lot to 
do with institutional issues. In 2009 the government launched new plans to reshape the National health-care 
system (Rein, 2009; RDPAC, 2008). According to the Guidelines on Deepening the Reform of Health-care 
System (Ye, Guocheng, 2009), the first phase of the reform aims to: increase the Basic Medical Insurance 
(BMI) to reach a 90% of population coverage by 2011; revise the reimbursable medicine under BMI, i.e. of 
the Essential Drugs List; set a more restrict regulation on prices by the National Development and Reform 
																																																								
1 “Over the past 30 years, China’s total fertility rate - the number of children a woman can expect to have during her lifetime - has 
fallen from 2.6, well above the rate needed to hold a population steady, to 1.56, well below that rate. Because very low fertility can 
become self-reinforcing, with children of one-child families wanting only one child themselves, China now probably faces a long 
period of ultra-low fertility, regardless of what happens to its one-child policy”. See The Economist, April  21st 2012.	
2 “People above the age of 60 now represent 13.3% of the total, up from 10.3% in 2000. In the same period, those under the age of 14 
declined from 23% to 17%”. See The Economist, May 5th 2011.	
3 China has more online shoppers (193 million) than any other country in the world. US has 170 million online consumers (Jingting, 
2012). “By 2015, China will add nearly 200 million users, reaching an Internet population of more that 700 million-almost double 
the combined number of Japan and the US” (see: Michael et al., 2012).	
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Commission (Deloitte, 2011, p. 3).  The second phase of the reform should bring into effectiveness a 
universal health care system, providing “safe, effective, convenient and affordable” health services to urban 
and rural residents (Ye, Guocheng, 2009). The 12th Five-Year Plan (2011-2016), released in 2011, has also 
put strong attention to health care and pharmaceutical industries (Tung, 2011; Deloitte, 2011). 
 
3. The changing shape of the Chinese pharmaceutical industry 
Healthcare reforms, while affecting consumptions, habits, and behaviours of Chinese people are having a 
significant impact on the industry, which is still highly fragmented (Yuanjia, Ung et al., 2007) and with 
strong rivalry. National firms compete and cooperate with foreign companies that have a direct presence in 
the market4. The three major firms - one Chinese and two big Western multinationals - share only 10% of the 
market. Yangtze River Pharmaceutical Group is the leading player (3.6% of the market’s value), 
AstraZeneca PLC controls 3.4% and Pfizer Inc. 3.0% (Datamonitor, 2010, p. 2). Bayern is gaining 
importance, as well. 
Distribution is highly fragmented. It is often criticised for its inefficiency and lack of transparency. China’s 
top three distributors - Sinopharm Group, Shanghai Pharmaceutical, and Guangdong Jiuzhoutong 
Pharmaceutical - had in combination less than 20% of overall market share in 2009. In the U.S., the top three 
pharmaceutical commerce companies together held a 96% market share (Deloitte, 2011).  
Above this general picture, in recent years, Chinese pharmaceutical market has made remarkable 
development, and its scale has increased rapidly. In 2010, the gross output of Chinese pharmaceutical market 
was $183.57 billions: $118.25 billions more compared to 2005. The industrial added value was $ 69.25 
billions, with an annual growth rate of 15.4%, larger than that of GDP and national industrial average 
growth. Total profit increased as well, at a rate higher than that of production value5. What’s more, from 
2000 to 2010, the number of pharmaceutical enterprises above the “designated size”6 increased from 3,301 to 
7,039; the value added tax was $1.39 billion in 2000, and increased to $ 8.08 billion in 2010. From 2000 to 
2010, revenues from principal business changed from $19.66 billion to $168.66 billion (see Exhibit 1). 
The number of firms has more than doubled from 2000 to 2010 and their scale has been also increasing. 
State-owned enterprises, foreign enterprises and private enterprises compete in the market (see Exhibit 2). 
Even if the number of private firms has more than doubled in only 6 years, their average size is much lower 
than SOEs and foreign firms. SOEs, on their side, have been experiencing a period of reorganization and 
rationalization: their number decreased from 1.500 to 500, but their average size grew significantly, as well 
as their gross domestic output.  
 
																																																								
4 From a geography perspective, most firms are located in the south-eastern zone, including two well developed areas (Zhejiang and 
Guandong provinces) and three underdeveloped areas (Hebei province, Heilongjiang province and Sichuan province). The 
motivation of this concentration can be found in the economic factors that draw the growth in last years. (Yuanjia, Ung et al., 2007, 
p. 19). 
5 See Ministry of Industry and Information Technology of the People’s Republic of China, 12th five-year plan of Chinese pharmacy 
market, See: http://news.pharmnet.com.cn/news/2012/01/20/352022.html. 
6 As stated by the National Bureau of Statistics of China, the relevant size is reached when revenue from principal business is more 
than 5 million yuan. 5 million yuan equal to 0.7386 million $ in 2010.	
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Exhibit 1 - Manufacture firms in the pharmaceutical industry, above designated size  
 
Year n. of enterprises  
Gross 
industrial 
output value 
($100 millions) 
Total assets 
($100 millions) 
Revenue from 
principal 
business  
($100 millions)
Total 
profits  
($100 millions) 
Value Added 
Tax Payable 
($100 millions) 
Annual average 
n. of employees 
(10,000 persons) 
2000 3301 215.18  338.10  196.59  16.50  13.94  83.00 
2001 3488 246.57  396.41  232.50  20.30  16.03  82.00 
2002 3681 287.36  446.25  275.46  24.33  18.14  82.00 
2003 4063 349.16  521.50  332.33  31.37  20.35  115.40 
2004 4397  579.70  388.19  33.78  22.41  118.51 
2005 4971 518.87  677.49  490.72  41.29  26.77  123.44 
2006 5368 629.59  769.77  591.94  46.73  30.68  130.28 
2007 5748 836.65  909.59  784.74  76.44  40.47  137.34 
2008 6524 1133.89  1134.90  1065.83  114.17  57.34  150.75 
2009 6807 1382.42  1367.49  1330.26  145.51  66.39  160.48 
2010 7039 1734.44  1642.13  1686.58  196.63  80.82  173.17 
Source: China Statistical Yearbook, several years. 
 
Exhibit 2 - The number and average size of pharmaceutical firms  
 
 
year 
Foreign Pharmaceutical 
Enterprises 
State-owned Pharmaceutical 
Enterprises 
Private Pharmaceutical 
Enterprises 
Other Kind of 
Enterprises7 
n. 
units 
(a) 
Gross 
industrial 
output value 
($100 mil) 
(b) 
 Average 
Size 
($100 mil) 
(b/a) 
n. nits 
(a) 
Gross 
industrial 
output 
Value 
($100 mil) 
(b) 
Average 
Size 
($100 mil) 
(b/a) 
n. 
units 
(a) 
Gross 
Industrial 
Output 
Value 
($100 mil) 
(b) 
Averag
e Size 
($100 
mil) 
(b/a) 
n. 
units 
(a) 
Gross 
Industrial 
Output 
Value 
($100 mil) 
(b/a) 
Averag
e Size 
($100 
mil) 
(b/a) 
2000 542 48.8 0.09 1496 106.78 0.07 - - - - - - 
2001 568 54.73 0.1 1341 110.43 0.08 - - - - - - 
2002 604 63.43 0.11 1180 116.71 0.1 - - - - - - 
2003 701 76.84 0.11 1001 128.43 0.13 - - - - - - 
2004 743 100.4 0.14 939 241.28 0.26 - - - - - - 
2005 890 127.93 0.14 676 124.27 0.18 1573 81.79 0.05 1832 184.98 0.10 
2006 955 159.44 0.17 590 124.94 0.21 1940 121.93 0.06 1883 223.26 0.12 
2007 1035 214.1 0.21 559 150.32 0.27 2198 171.75 0.08 1956 300.43 0.15 
2008 1144 307.12 0.27 527 175.09 0.33 2669 261.05 0.1 2184 390.57 0.18 
2009 1144 386.18 0.34 508 175.38 0.35 2911 334.8 0.12 2244 486.01 0.22 
2010 1140 468.42 0.41 507 223.06 0.44 3118 449.81 0.14 2274 592.99 0.26 
Source: China Statistical Yearbook, several years. 
 
Pushed by factors of market growth, technical progress, increased investment and mergers and 
reorganization, some large-scale enterprises are appearing in China and they are becoming leaders in basic 
drugs supply. There was only 1 pharmaceutical firm with more than 10 billion yuan ($1.22 billion) sale 
proceeds in 2005, while in 2010 they were 10. In 2010, 1,125 out of the 7,039 pharmaceutical firms in the 
market were large and medium-sized8, controlling 694.8 billion yuan ($102.64 billion) of the pharmaceutical 
industrial output value (59.17% of total value). Pharmaceutical enterprises with more than 5 billion yuan 
																																																								
7	Other Kind of Enterprises includes: collective-owned enterprises, share-holding cooperative enterprises, share-holding enterprises.	
8 Large-sized industrial enterprises means that the number of employed persons is more than 2000, the sale revenue is more than 300 
millions yuan (44.31 millions $ in 2010), the total assets is more than 400 millions yuan (59.09 millions $ in 2010). Medium-sized 
Industrial Enterprises means that the number of employed persons is between 300 and 2000, the sale revenue is between 30 and 300 
millions yuan (4.43-44.31 millions $ in 2010), the total assets is between 40 and 400 millions yuan (5.91-59.09 millions $ in 2010).	
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($0.61 billion) sales were 17 in 2010, while only 3 in 20059. Among them, Yangtze River Pharmaceutical 
Group, Harbin pharmaceutical Group, China Shijiazhuang Pharmaceutical Company, TongRenTang, 
Guangzhou Pharmaceuticals Corporation, Weigao Holding Co. Ltd are gaining market shares.  
At the same time, new enterprises, such as Jiangsu Hengrui Medicine Co., Zhejiang Hisun Pharmaceutical 
Co. Ltd., Tasly Group, Shineway Pharmaceutical Group, Mindray, are developing rapidly. Some backbone 
enterprises, such as China National Pharmaceutical Group Corporation, Shanghai Pharmaceutical Co.,Ltd., 
Sino-Swed Pharmaceutical Corp.Ltd., are also growing rapidly by merger and acquisition, achieving 
integration of industry chain, enhancing their competitiveness.  
Enterprises listed in Exhibit 3 were the top 20 firms in Chinese pharmacy market. Yangtze River 
Pharmaceutical Group is the first as for prime operating revenue, while Shanghai Pharmaceutical (group) Co. 
Ltd had most gross assets. Looking at total profit, China National Pharmaceutical Group Corporation ranked 
first. 
Exhibit 3 – Financial and economic data: ranking the top 20 firms in 2011  
Ranking Prime operating revenue Gross assets Total profit 
1 Yangtze River Pharmaceutical Group Shanghai Pharmaceutical (group) Co.,Ltd. China National Pharmaceutical Group Corporation 
2 Xiuzheng Pharmaceutical Group Co. Ltd. China Shijiazhuang Pharmaceutical Company Weigao Holding Company Limited 
3 Shanghai Pharmaceutical(group) Co. Ltd. Tasly Group Shanghai Pharmaceutical(group) Co.,Ltd. 
4 Harbin pharmaceutical group Harbin pharmaceutical group Shandong Buchang Pharmaceutical Co., Ltd.  
5 China Shijiazhuang Pharmaceutical 
Company Kangmei Pharmaceutical Co.,Ltd Yangtze River Pharmaceutical Group 
6 Tasly Group 
 
China National Pharmaceutical Group 
Corporation NHU Group Co., Ltd. 
7 Weigao Holding Company Limited Weigao Holding Company Limited Harbin pharmaceutical group 
8 Yunnan Baiyao Group Company Limited Yangtze River Pharmaceutical Group Yunnan Baiyao Group Company Limited 
9 China National Pharmaceutical Group 
Corporation Sichuan Kelun Pharmaceutical Co., Ltd. Tasly Group 
10 Guangzhou Pharmaceuticals Corporation Qilu Pharmaceutical CO.,LTD. Qilu Pharmaceutical CO.,LTD. 
11 Bayer Group Zhejiang Jianfeng Pharmaceutical Holdings Hangzhou Sainuofei Anwante Minsheng Pharmaceutical Co., Ltd. 
12 Taiji Group Co., Ltd. Xiuzheng Pharmaceutical Group Co.,Ltd. Guangzhou Pharmaceuticals Corporation 
13 Northeast Pharmaceutical Group Co., Ltd. Guangzhou Pharmaceuticals Corporation Sichuan Kelun Pharmaceutical Co., Ltd. 
14 Tianjin Zhongxin Pharmaceutical Group 
Corporation Limited Yunnan Baiyao Group Company Limited Kangmei Pharmaceutical Co.,Ltd. 
15 HeiLongJiang ZBD Pharmaceutical 
Co.,Ltd. Furen Medicine Group Zhejiang Medicine Co., Ltd. 
16 Hangzhou Zhongmei Huadong 
Pharmaceutical Co., Ltd. NHU Group Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd. 
17 Sichuan Kelun Pharmaceutical Co., Ltd. Taiji Group Co., Ltd China Resources Dongeejiao Co.Ltd 
18 Beijing Double-Crane Pharmaceutical 
Business Co., Ltd. Zhejiang Hisun Pharmaceutical Co,.Ltd. Xiuzheng Pharmaceutical Group Co.,Ltd. 
19 Shanghai Roche Pharmaceutical Co., Ltd.  Northeast Pharmaceutical Group Co., Ltd China Shineway Pharmaceutical Group 
20 Shandong Buchang Pharmaceutical Co., 
Ltd.  Lunan Pharmaceutical Group Corporation 
Jiangsu Chia-tai Tianqing Pharmaceutical 
Co., Ltd. 
Source: Ministry of Industry and Information Technology of the People’s Republic of China, The rank of manufacture firms in the 
pharmaceutical industry in 2011,http://xfps.miit.gov.cn/n11293472/n11295176/n11298973/14522230.html. 
 
There are more and more foreign enterprises in China and their size is also increasing. From the absolute 
value of indicators, we can find that there were only 542 enterprises in 2000, while in 2010 they were 1,140. 
																																																								
9 Ministry of Industry and Information Technology of the People’s Republic of China,12th five-year plan of Chinese pharmacy 
market,http://news.pharmnet.com.cn/news/2012/01/20/352022.html. 	
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The total assets they hold moved from $6.4 billions to $44.34 in 2010. In 2010, revenues from principal 
business reached 44.77 billion (ten times of that in 2000), while total profit was about 6 billion in 2010 (15 
times of that in 2000). See Exhibit 4. 
Exhibit 4 - Main Indicators of foreign firms in the Chinese market     
Year n. 
unit 
Gross industrial 
output value  
($100 million) 
Total assets 
($100 million) 
Revenue from 
principal business 
($100 million) 
Total profits 
($100 million) 
Value added tax 
payable  
($100 million) 
Annual average 
number of 
employees  
(10,000 persons)
2000 542 48.77  64.00  44.19  3.97  3.64  - 
2001 568 54.76  70.11  51.05  4.69  4.17  - 
2002 604 63.41  78.68  59.82  5.58  4.92  - 
2003 701 76.84  93.34  69.67  8.37  5.29  16.92 
2004 743 - 100.35  76.96  9.16  5.50  16.63 
2005 890 127.92  145.06  118.05  12.60  8.27  22.62 
2006 955 159.44  169.67  148.84  14.78  9.55  25.29 
2007 1035 214.11  218.87  198.40  24.81  12.87  27.40 
2008 1144 307.19  303.03  287.39  37.45  18.71  31.77 
2009 1144 386.23  375.34  372.69  48.31  22.20  34.77 
2010 1140 468.47  443.41  447.74  60.75  26.72  38.21 
Source: China Statistical Yearbook, several years. 
In 2010, firms from abroad produced 27.01% of gross industrial output value, 26.55% of prime operating 
revenue, 30.89% of total profit, and 27.1% of total assets (Exhibit 5). Anyway, despite the importance of 
foreign companies, their share in the market is not overtaking national firms, that are keeping their role and 
competitive position. 
Competition and rivalry among foreign firms and Chinese companies is going to be strongly affected by the 
changing landscape in proprietary technology. At the moment, foreigners hold the monopoly in many 
proprietary technologies. In the insulin market only, Novo Nordisk, Eli Lilly and Sanofi controlled more than 
90% of the sales in 201010. This situation is going to change rapidly. In fact, more than 10 of the world’s 
best-selling drugs, including Pfizer’s cholesterol-lowering Lipitor and Lilly’s antipsychotic Zyprexa, lost 
patent protection in 2011. This is expected to directly result in a nearly US$5 billion reduction in those 
global pharmaceutical companies’ revenue. Furthermore, it is estimated that more drugs valued at about 77 
billion $ in total are going off patent within the next five years. Generic drugs are the mainstay of China’s 
pharmaceutical industry, and are likely to remain so for a long time (Deloitte, 2011). In this regard, foreign 
enterprises should play a more and more important role in Chinese non-Generic drugs market, while Chinese 
state-owned firms and private companies should have a relevant market share in the generic drug market. 
Exhibit 5 - The role of foreign enterprises in the pharmaceutical market (% of total market)     
Year Number of Enterprises  Gross industrial output value Total assets Prime operating revenue Total profit 
2000 16.42 22.66 18.93 22.48 24.06 
2001 16.28 22.21 17.69 21.96 23.08 
2002 16.41 22.07 17.63 21.71 22.92 
2003 17.25 22.01 17.90 20.97 26.69 
2004 16.90 --- 17.31 19.82 27.13 
2005 17.90 24.65 21.41 24.06 30.52 
2006 17.79 25.32 22.04 25.15 31.62 
2007 18.01 25.59 24.06 25.28 32.46 
2008 17.54 27.09 26.70 26.96 32.80 
2009 16.81 27.94 27.45 28.02 33.20 
2010 16.20 27.01 27.00 26.55 30.89 
Source: China Statistical Yearbook, several years. 
																																																								
10 See: China Medical Association, The Development of Insulin Market in China, http://www.chinamsr.com/2011/0124/21748.shtml.	
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4. The foreigners’ hunger for China 
As shown in the previous paragraphs, foreign firms play an increasing role in China. Most of them have 
made collaborative partnerships with Chinese companies to start manufacturing plants, business operations 
facilities, marketing divisions, and research facilities. 
As a result of the Open Door Policy, China has been attracting huge flows of FDIs and has become the first 
recipient of FDI among emerging market, the second after the US in absolute term (Unctad, WIR, 2011). 
The Chinese pharmaceutical industry has been one of the most interesting target for foreign investors. At the 
end of 1998, there were 1,500 pharmaceutical firms with foreign ownership (Jiang, 2005, p. 22). Since 2000, 
investments have nearly doubled (see Exhibit 6). Large multinational groups from North America, Western 
Europe, and Asia were attracted to China, as a result of a more friendly and favourable business and 
institutional environment. Operating in the Chinese market is still considered high-risky, time-consuming 
and expensive compared to other emerging markets due to stringent regulations concerning safety and 
efficacy. Anyway, the interest for China is increasing and several factors can explain this trend.	
 
Exhibit 6. Inward FDI in China in the Medical & Pharmaceutical Product sector (million US dollars)  
Source: own calculation on data provided by CeSif, Fondazione Italia Cina - Ceic 
 
First of all, China is an important sales market for the internal, booming demand (Jiang, 2005)11. As 
mentioned above, China is supposed to become the second world largest pharmaceutical market by 2020, as 
a result of demographic changes, improved life standards, government actions. Upgrading health care 
behaviours and consumptions, Chinese people are changing their attitude towards Traditional Chinese 
Medicine practices. Western medicines are considered more effective, especially as for life-saving drugs are 
concerned, antibiotics most of all.  
China is also strategic for Western companies to reach other nearby Asian emerging markets: as operating in 
the country can offer a logistic and commercial platform to penetrate them.  
Second factor, China is a market for delocalizing the production of high quality and price competitive raw 
materials. In some specific market segment (antibiotics, cephalosporin o other high chemical substances), 
																																																								
11 In the study developed by Jiang (2005) on determinants of FDI into China, the author found out that FDIs were pushed mainly by 
China’s specific location factors. China’s market size and its potentials played the most important role. Other relevant motivations 
were: rapid economic development and growth, China’s Open Door Policy and relatively stable political conditions.	
		 9
producing in China is a necessity. In the West, in fact, environmental and safety rules make it impossible to 
set up fermentation and chemical plants associated with pharmaceutical plants. 
The delocalization phenomenon is not recent. Internationalization in China began in the middle 80’s, when 
important pharmaceutical groups settled fermentation plants in the North of the country to produce basic 
products for antibiotics. During the ’90, production in China evolved, including more sophisticated 
products/materials. Nowadays, China is the world leader in the production of pharmaceutical base materials, 
that are then re-imported in the Western markets to produce finished goods (medicines). This phenomenon 
could justify the huge increase in imports and exports volumes, as well. See exhibit 2. 
Third aspect, China is the frontier to develop applied research programs. Big players such as Novartis, 
Pfizer, Merck Serono, AstraZeneca, Roche have established research centres in China (see box 1 and Exhibit 
B in Appendix). The strategic idea is to leave good R&D departments in the country of origin to develop 
basic programs. The implementation phases and applied research activities are carried out in China, to 
reduce time for drug improvement and to cut costs (Datamonitor, 2009, p. 13). The core phases related to 
market entry of a new drug are left in the West, partly because of stringent rules of trials required by the U.S. 
and European agencies12. All other, subsequent, trials and market extension activities are developed in 
China, where skilled labour workforce, talented scientists and leading University research centres are 
available (Tung, 2011).  
China is more and more considered as a platform to develop innovative drugs (Choy et al., 2011, p. 6). The 
booming success of Chinese Contract Research Organizations (CROs) - the backbone of Chinese R&D - is a 
proof of this phenomena. They support the pharmaceutical and biotechnology industries on a contract basis, 
providing specific services: biopharmaceutical development, preclinical research, clinical research, as well as 
clinical trials management13.  
Chinese CROs are expanding the activity of the value chain that they can serve (see Exhibit A in Appendix), 
and thus upgrading their role in the Chinese pharma industry. They range from large and global 
organizations to niche specialty groups, offering reduced costs and high flexibility.  “Almost every global 
biopharma company outsources at least some of its R&D activities to China” (BCG, 2011, p. 2). Industry 
projections forecast an increase role of CROs as high quality service providers, both for longlasting 
cooperation and for a “one-stop” shop approach. CRO are considered as a valuable source of innovation for 
Western pharmaceutical companies to develop strategic alliances to boost both research and development of 
new products. At the same time, CRO are economic and effective way for buying “on demand” innovation to 
face specific and/or unplanned needs. 
 
 
 
																																																								
12 “The globalisation process of industry-sponsored clinical trials is growing. More and more study sites are located outside North 
America and Europe, especially phase III trials. From the latest analysis, there are now more phase II-III trial sites in the rest of the 
world (ROW) than Europe; 27.0% versus 24.6%, respectively. […] The major emerging regions are still Eastern Europe, Asia and 
Latin America”. Cfr. Karlberg, Speers, 2010, p. 58.	
13 At the end of 2007 the value of R&D outsourced to China, mostly through CROs, was worth $550 million (Shen, 2008).	
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Box 1 - Major Western pharmaceutical R&D centers in China 
AstraZeneca 
Innovation Center China (ICC) opened its lab facilities in Zhangjiang Hi-tech Park in October 2007. ICC’s presence is traced back to the 
announcement, in May 2006, of a large $100 million R&D investment in China. The initial concentration is on cancer through the development of 
knowledge about Chinese patients, biomarkers and genetics. Researchers at the facility work on the identification, development and validation of new 
biomarkers. The centre also draws on the extensive alternative compound resources of AstraZeneca to analyse and select suitable drugs for Chinese 
patients. These also provide useful data for further decision-making in clinical trials (http://en.astrazeneca.com) 
Bayern 
Bayer, a leading healthcare product manufacturer, has been developing an investment plan in China since 2009 to establish a research and 
development (R&D) center in Beijing, the company’s first foot in Asia. “China is home to a large pool of skilled medical and scientific talents. Our 
goal is to work closely together with our Chinese partners to support China conducting their own R&D activities and at the same time we will be able 
to strengthen our own R&D capabilities” (http://www.bayer.cn/index.php/NewsCenter/newsDetail/id/161?l=en-us). 
Merck Serono 
Merck Serono has recently established a global R&D center in Beijing, supported by a four year investment of $225 million. The center, which will 
eventually house 200 employees, will be the fourth major R&D center for the company (http://seekingalpha.com). 
Novartis 
Novartis, in 2009, announced its five year plans to invest $1.25 billion in its two Chinese R&D centers. In 2007 the Novartis Institute of BioMedical 
Research was opened in Shanghai (http://www.businessweek.com/globalbiz/content/nov2009/gb2009113_520982.htm). Two years later another 
center was established in Changshu, near Shanghai, to develop and manufacture active pharmaceutical ingredients (API). In March 2011, Novartis 
expanded its presence in the Chinese vaccine market by acquiring an 85 percent stake in Zhejiang Tianyuan Bio-Pharmaceutical Co Ltd, one of the 
largest private vaccine companies in China (Tung, 2011). 
Pfizer  
Pfizer recently has been undertaking a series of initiatives in China to tap the expertise of Chinese academics and professionals. The aim is to enhance 
its capabilities in the research and development field. Pfizer has grown its work force at its Shanghai R&D center to 342 from the 14 hired in 2005, 
when the center was established (Yan, 2009). After Shanghai, in 2010, Pfizer completed a greenfield scientific center in Wuhan in China’s midwest 
region, in the Biolake scientific park. 
Roche 
Roche has established the R&D Centre China LTD (RRDCC) in 2004 in Zhangjiang Hi-Tech Park in Shanghai, for pharmaceutical R&D, employing 
about 100 people (Burkitt, 2010). The group also controls in China: Roche Holding Shanghai, Roche Diagnostics (Shanghai) Limited, Shanghai 
Roche Pharmaceuticals Limited. 
 
Part of the interest of key Western pharmaceutical companies into the Chinese market can also be related to 
the potentials of Traditional Chinese Medicine – TCM (Shen, 2008, p. 22).  
The popularity of alternative or holistic medicines has increased significantly in recent years within the 
general public (Datamonitor, 2010, p. 15). Annual global trade in herbal medicine has surpassed $40 billion, 
with an annual growth rate of 10 percent (Zhang, 2011). Chinese companies do not have a primary role in 
this market. China had nearly 4,700 herbal medicine companies by the end of 2010, with annual output 
worth 1.2 trillion yuan ($186.5 billion). The sector is fragmented, with the top 10 formulated TCM 
companies accounting for 14% of total market share. Local companies, including many state-owned 
enterprises dominate the internal Chinese market (PWC, 2009, p. 4). 
Most of China’s herbal medicine companies have a low internationalization profile (Zhang, 2011). Only 
about 3 percent of the global TCM market is in the Chinese’s hands. There is therefore huge space for 
partnership and alliances by Western companies that could help pushing the Chinese firm in the international 
arena. One of the key problems in expanding abroad is related to intellectual property rights, trademark 
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registration and patent applications. Chinese companies are still weak in promoting their products on the 
global market (Zhang, 2011)14.  
 
5. Patenting trends 
Technological innovation achievements in the Chinese pharmaceutical market are remarkable. 3 billion $ 
were invested in innovation medicine by government in the form of “significant new drug”, attracting also 
non-public funds into the sector. More than 50 state-level technical centers were built up in the form of 
“Industry-University-Institute” Cooperation programs. Innovative Medicines, such as Antofloxacin 
hydrochloride and recombinant Helicobacter pylori vaccine, were approved. Some Monoclonal antibody 
agents, such as Recombinant Human Tumor Necrosis Factor, had achieved industrialization. Breakthrough 
was made in cells culture in a large scale and biocatalysis and so on. The production technology of some 
products, such as amoxicillin and Vitamin E, was enhanced. Achievements were made in the area of product 
and technology development15. 
In such a flourishing environment, China has been very active in patent applications. According to the 
statistics from WIPO in 2011, the quantity of Chinese patent applications was increasing rapidly compared 
with other leading countries. China applied 10,894 patents in 2010, which was 7 times of that in 2000. China 
became the second largest patent application country after US exceeding Japan and German in 2005 (see 
Exhibit 7). 
 
Exhibit 7 - The pharmaceutical patent application by leading countries (2000-2009) 
Year 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
The United States of America 9,989 11,386 15,069 16,877 18,584 21,872 22,155 21,884 20,957 19,497 
China 1,347 2,509 3,445 4,178 4,689 8,385 9,578 11,157 10,962 10,894 
Japan 2,949 3,240 3,814 4,514 5,112 5,528 5,694 5,358 5,165 5,297 
Germany 2,708 2,990 3,965 4,428 4,727 5,236 4,814 4,229 3,899 3,649 
Switzerland 854 1,129 1,504 1,993 2,598 2,991 2,839 3,098 3,332 2,992 
France 1,647 1,667 1,875 1,881 2,134 2,159 2,174 2,234 2,326 2,488 
Britain 1,933 1,866 1,944 2,122 2,306 2,268 2,203 2,215 2,184 2,103 
The Republic of Korea 518 648 880 1,089 1,140 1,295 1,186 1,149 1,342 1,842 
Source: WIPO Statistics Database, 2011, based on the WIPO IPC-Technology concordance table. 
 
Considering the industrial sectors involved in patenting in China, from 2000 to 2008, pharmaceutical has 
been the industrial sector that applied the highest number of patents (see Exhibit 8).  
 
 
 
																																																								
14 The case of European market is significant. It is the second world’s largest market for herbal medicine, after China. The position of 
Chinese companies is neglectable. Consider that after the European directive in 2004, regulating herbal medicines, a company must 
demonstrate that a herbal medicine has been in use for at least 30 years, including 15 years in the EU. “It must also get a certificate 
that it meets standards for quality and safety. In the seven years following adoption of the regulation, none of the 350 newly 
authorized herbal medicines came from China” (Zhang, 2011).	
15 Ministry of Industry and Information Technology of the People’s Republic of China: 12th five-year plan of Chinese pharmacy 
market. http://news.pharmnet.com.cn/news/2012/01/20/352022.html.	
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Exhibit 8 - Patent applications published by field of Technology from 2000 to 2009, in China 
Year 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
Pharmaceuticals 1,347 2,509 3,445 4,178 4,689 8,385 9,578 11,157 10,962 10,894 
Telecommunications 270 534 933 1,697 2,376 3,560 5,679 7,190 10,055 6,782 
Computer technology 778 1,156 1,740 2,683 3,346 4,710 5,226 7,336 9,645 11,818 
Biotechnology 428 2,570 2,198 1,343 1,561 2,329 2,472 2,787 3,873 4,574 
Chemical engineering 428 578 692 1,053 1,131 1,877 2,191 2,884 4,061 4,785 
Environmental technology 344 477 656 862 1,030 1,688 1,967 2,308 3,232 4,020 
Source: WIPO Statistics Database, 2011, based on the WIPO IPC-Technology concordance table. 
 
Domestic firms lead the patent application market (see Exhibit 9). Taking medicine manufacturing industry 
as an example, there were only 273 patent applications in 1995, and this number increased to 8,601 in 2009 
which was almost 30 times of that in 2000. There were only 183 patents granted in 1995, and this number 
increased to 6,017 in 2009. In the meantime, the patent applications and granted patents of foreign 
enterprises were also increasing. From 23 patent applications made by foreign enterprises in 1995, the 
number increased to 923 in 2009, while granted patents increased from 19 in 1995 to 986 in 2009.  
Patents are becoming more and more popular also for TCM. The Chinese State Intellectual Property reported 
that since 1985, more than 68,000 TCM patents were registered. Over 66,000 of them were from domestic 
applicants (Jingjing, 2010). At the same time, China has applied for 3,000 TCM patents in foreign countries, 
but foreign countries applied for more than 10,000 TCM patents in China. Big pharmaceutical players have 
not a significant “place” in this market jet. Consider that only GlaxoSmithKline has registred in 1997 a TCM 
patent on “a pharmaceutical composition for the prevention and treatment of gastrointestinal diseases, and its 
preparation method”16, while Roche has registred two TCM patents: on “the use of erythropoietin and iron 
preparations for producing pharmaceutical combination preparations for treating rheumatic diseases” and the 
other on “hedgelog protein medicinal composition and its use/a protein solution and its use”. Other Western 
important players do not appear in the database of Traditional Chinese Medicine patents (Spigarelli, Farah, 
Filippetti, 2012).  
Exhibit 9 - Patent application and patent granted in Chinese manufacturing industry (1995-2000) 
Year Total  Foreign enterprises Foreign enterprises (proportion, %)
Patent application Patent granted Patent application Patent granted Patent application Patent granted
1995 273 183 23 19 8.42 10.38
1996 168 113 67 54 39.88 47.79
1997 257 134 38 25 14.79 18.66
1998 275 224 95 62 34.55 27.68
1999 283 232 30 16 10.60 6.90
2000 547 414 87 168 15.90 40.58
2001 735 308 139 62 18.91 20.13
2002 999 484 70 64 7.01 13.22
2003 1,305 459 208 91 15.94 19.83
2004 1,696 902 354 145 20.87 16.08
2005 2,708 1,134 594 273 21.94 24.07
2006 2,383 1,965 575 495 24.13 25.19
2007 3,056 2,482 589 747 19.27 30.10
2008 3,917 3,170 863 853 22.03 26.91
2009 8,601 6,017 923 766 10.73 12.73
2010 5,767 5,672 841 986 14.58 17.38
Source: China Statistical Yearbook On High Technology Industry, several years. 
 
																																																								
16 See http://chmp.cnipr.cn/englishversion/help/help.html.	
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Chinese consumers have high confidence in foreign patented brands, that – as a result - are expected to win 
drug customers away from the domestic generic brands, causing their proportional market shares to shift 
accordingly. Sales of patented drugs, which rocketed upward at a CAGR of 35.7 percent from 2007 through 
2010, are forecast to continue growing at just over 25 percent from 2010 through 2015 (Deloitte, 2011). 
The increasing role of foreign enterprises in patent applications and granted patents can be considered a 
combined consequence of improved IP protection made by the Government and of the booming 
pharmaceutical demand in China.  
The Government has adopted industrial and regulatory policies, such as preferential drug pricing and 
hospital drug procurement policies, that favour research-based MNCs and large domestic enterprises. At the 
same time, it has improved market access for foreign companies and taken steps to strengthen intellectual 
property protection to foster innovation. A huge effort has been made also to regulate and approve APIs and 
audit drug production facilities (Shen, 2008, p. 21). 
Despite such policies, however, foreign companies remain concerned with certain areas of IP protection in 
the pharmaceutical sector. Specifically, the central government has not (Shen, 2008) yet clearly defined 
“new chemical entity” in a drug, which would make ensuring data exclusivity during drug registration 
difficult. More over, it has not adequately protected against unfair commercial use of undisclosed test and 
other data submitted by pharmaceuticals companies. A more robust system of patent linkage under which the 
filing of a lawsuit will automatically suspend the registration process of a product suspected of infringement 
is missing. At the same time, there is a lack of a system of patent-term restoration to help innovative 
companies recover patent-term losses due to long development time and regulatory delays. 
 
6. Conclusions 
Major players of the World pharmaceutical market are investing in China, where they can have access to a 
rapidly growing market to sell Western products, as well as to incentives and facilities to develop high level 
R&D activities.  
An R&D driven re-evolution of the market is taking place, thanks to the Government’s policies aiming at 
building a friendly environment for Western firms, attracted in China not only to be partners of local actors 
and grasp knowledge from them, but also to become customers of a more and more qualified R&D oriented 
supply. At the same time, the Government is supporting the growth of global-national champions, 
reorganizing SOEs and pushing new private pharmaceutical firms. The rise of Chinese innovative and large 
multinationals is promoted (Shen, 2008, p. 21). 
The role of industrial policies is thus fundamental to understand the scope of changes undergoing in China.  
Huge efforts in R&D is resulting in booming patents in the field: pharmaceuticals is the industrial sector 
which applied the highest number of patents in recent years. Domestic enterprises are the main force, but 
patent applications and granted patents of foreign enterprises are increasing as well. Acquisition of 
distinctive knowledge (as far as TCM is involved) does not seem to be strategic, for Western companies 
entering the Chinese market. TCM industry and patents are currently dominated by national firms. 
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In sum, Chinese market seems to be evolving into a highly competitive marketplace, where Chinese firms 
are training not only to keep market shares compared to Western firms, but also to conquer an active and 
strategic position in the global value chain of the Wold pharmaceutical market. 
	
	
 
		 15
 
References 
Burkitt L. (2010), “Roche Boosts Presence in China”, The Wall Street Journal, Sept. 8th  
Business Monitor International Ltd (2011), China Pharmaceuticals & Healthcare Report Q3 2011. 
Executive Summary, (available at: 
http://store.businessmonitor.com/products/?action=download&type=exec_summary&product_id=153201
1. Last access January 30th, 2012). 
Choy M., Lee R., Wong J. (2011), Biopharma R&D in China, BCG (available at: https:// 
bcgperspectives.cm/content/articles. Last access April 30th, 2012). 
Datamonitor (2010), Pharmaceuticals in China, ref. 0099 - 0372. 
Datamonitor (2011), Pharmaceuticals in China, ref. 0099-0372. 
Deloitte (2010), Life Sciences and Health Care in China Opportunities, challenges and implications 
(available at www.deloitte.com/.../681921%20China%20POV_High%20Resolution.pdf. Last access April 
30th  2012). 
Deloitte (2011), China’s pharmaceutical market: summary and prospects, 
www.deloitte.com/view/en_GX/global/industries/life.../index.htm. Last access April 30th  2012). 
EIU (2009), Business China, April 13th. 
Eunjung Cha A., Fan M. (2008), “China Unveils $586 Billion Stimulus Plan”, Washington Post Foreign 
Service, Nov. 10th, http://www.washingtonpost.com/wp-
dyn/content/article/2008/11/09/AR2008110900701.html  
Hu A. G., Jefferson G.H. (2009), “A great wall of patents: What is behind China’s recent patent explosion?” 
Journal of Development Economics, 90(1):57-68. 
Hutchinson M. (2011), “IMF Forecast: Can China Really Overtake the U.S. Economy by 2016?”, 
Moneymorning, April 28th  (available at: http://moneymorning.com/2011/04/28/imf-forecast-can-china-
really-overtake-the-u-s-economy-by-2016. Last access January 30th 2012). 
ICE (2009), Chinese Market of Chemical Products, Shanghai Office, ICE. 
IMS (2010), “Strategies for emerging markets: 7 keys to the Kingdom”, Pharmaceutical Executives, vol 30 
(8), (available at: 
http://www.imshealth.com/deployedfiles/ims/Global/Content/Innovation/Powering%20Client%20Transfo
rmation/Emerging%20Markets/emerging_markets_seven_keys_to_kingdom.pdf . Last access January 30th 
2012). 
IMS (2011), The Global Use of Medicines: Outlook Through 2015, (available at: 
http://www.imshealth.com/portal/site/ims/menuitem.edb2b81823f67dab41d84b903208c22a/?vgnextoid=
2f78cb79461bf210VgnVCM10000071812ca2RCRD&vgnextfmt=default . Last access January 30th 2012) 
Jan-Willem E. (2011), China and the New Harbingers of Change, IMS, (available at: 
http://www.imshealth.com/deployedfiles/ims/Global/Content/Innovation/Powering%20Client%20Transfo
rmation/Emerging%20Markets/IMS_Harberingers_of_Change.pdf. Last access January 30th 2012). 
Jiang F. (2005), “Driving forces of International Pharmaceutical Firms’ FDI into China”, Journal of Business 
Strategies, vol. 22 (1). 
Jingjing H. (2010), “TCM growing pains”, Global Times, Oct. 22nd (available at: 
http://china.globaltimes.cn/society/2011-04/584559_2.html. Last access January 30th 2012). 
Jingting S. (2012), “China's online retail sector set to surpass US' around 2015”, China Daily, April 13th 
2012 (available at: http://www.chinadaily.com.cn/bizchina/2012-04/13/content_15038696.htm. Last access 
April 30th, 2012). 
Karlberg J., Speers M.A. (2010), Reviewing Clinical Trials: A Guide for the Ethics Committee, Karlberg, 
Johan Petter Einar, Hong Kong, (available at: 
http://media.pfizer.com/files/research/research_clinical_trials/ethics_committee_guide.pdf . Last access 
January 30th 2012) 
Michael D., Nettesheim C., Zhou I. (2012), China’s Digital Generations 3.0: The Online Empire, BCG 
(available at: 
https//www.bcgperspectives.cm/content/digital_economy_globalization_china_digital_3_0_online_empire/ 
Last access April 30th, 2012). 
PriceWaterhouseCoopers – PWC (2009), Investing in China’s Pharmaceutical Industry – 2nd Edition 
(available at: http://www.pwc.com/gx/en/pharma-life-sciences/investing-china/index.jhtml. Last access 
June 20th 2012). 
		 16
Rabinovitch S. (2011), “China’s foreign reserves climb by $153bn”, Financial Times, July 12, 
http://www.ft.com/intl/cms/s/0/13c382e6-ac59-11e0-bac9-00144feabdc0.html#axzz1ebWgynIu  
Rader R. (2005), “What Is a Biopharmaceutical? Part 2: Company and Industry Definitions”, BioExecutive, 
May 2005. 
Reichman J.H. (1998), “Securing Compliance with the TRIPS Agreement after US v India”, Journal of 
International Economic Law, 1(4): 585-601. 
Rein S., “Health-Care Reform, China Style”, Bloomberg Businessweek, 
http://www.businessweek.com/globalbiz/content/aug2009/gb20090821_005732.htm, Aug. 21st (2009) 
Sell, S.K. 2003. Private Power, Public Law. The Globalization of Intellectual Property Rights. Cambridge: 
Cambridge University Press. 
Shadlen, Kenneth C. 2012. Intellectual Property, Pharmaceuticals, and Public Health: Access to  Drugs in 
Developing. Edward Elgar Publishing. 
Shen J. (2008), “China rising importance in Pharmaceuticals”, China Business Review, may-june, pp. 21-38. 
Shen J. (2011), China Pharmaceutical Guide, WiCON International Group LLC, Princeton, US (available at: 
http://www.pharmachinaonline.com/upfiles/UploadFiles/201162854527543.pdf. Last access June 20th 2012). 
Sirkin H., Zinser M., Hohner D. (2011), “Made in America, Again. Why Manufacturing Will Return to the 
U.S.”, BCG report, August 25th (available at 
https://www.bcgperspectives.com/content/articles/manufacturing_supply_chain_management_made_in_ame
rica_again/. Last access April 30th  2012). 
The Economist (2011), “The most surprising demographic crisis”, May 5th (available at: 
http://www.economist.com/node/18651512. Last access April 30th 2012). 
The Economist (2012), “China’s Achilles heel”, April 21st (available at: 
http://www.economist.com/node/21553056?fsrc=scn/tw/te/ar/chinasachillesheel. Last access April 30th, 
2012). 
Tung A. (2011), “Alliances form in growing pharmaceutical  market”, China Daily, Aug. 3rd. 
Unctad (2011), World Investment Report, Non-equity modes of international production and development, 
http://www.unctad.org/Templates/WebFlyer.asp?intItemID=6018&lang=1 
Unctad, Word Investment Report, several years. 
Wan J. (2008), “Report from China”, Pharmaceutical Technology, 2008. 
Wenley D. (2010), “The World's Top Choice. China remains the most popular destination for foreign direct 
investment”, Beijing Review, n. 38, Sept. 23rd  
Wipo, The International Patent System, Yearly Review, Developments and Performance in 2010, 
www.wipo.int/pct/en/activity/pct_2010.pdf (2011). 
Ye Y., Guocheng J. (2009), “China unveils health-care reform guidelines”, Xinhua, 
http://news.xinhuanet.com/english/2009-04/06/content_11138643.htm, April 6th. 
Yuanjia H., Geng F., Ying B., Yitao W. (2007), “The Chinese pharmaceutical market: Perspectives of the 
health consumer”, Journal of Medical Marketing, vol. 7 (4), pp. 295-300. 
Yuanjia H., Ung C., Ying B., Yitao W. (2007),“The Chinese pharmaceutical market: Dynamics and a 
proposed investment strategy”, Journal of Medical Marketing, vol. 7 (1), pp. 18-24. 
Zhang Y. (2009), “High performance work practice and firm performance: evidence from the pharmaceutical 
industry in China“, The International Journal of Human Resource Management, vol. 20 (11), pp. 2331-2348. 
Zhang Z. (2011), “Meeting the EU formula to market herbal medicines”, China Daily, Aug. 10th. 
Zhou Y. (2009), “Pfizer grows R&D work in China”, China Daily, 
http://www.chinadaily.com.cn/business/2009-08/10/content_8548101.htm, Aug. 10th. 
 
 
		 17
 
Annex 
Exhibit A Chinese CROs: their role in the industry value chain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: BCG, 2011. 
 
Exhibit B Main foreign investment initiatives in China in the R&D sector 
 
 
 
 
 
 
 
 
 
 
Source: BCG, 2011. 
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Exhibit C Main Steps in the Chinese Healthcare reform 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Deloitte, 2011, p. 3. 
 
